Sutro Biopharma, Inc. STRO 深 沪
等待开盘 05-21 09:30:00 美东时间
31.13
-0.540
-1.71%
华盛通- 最 高32.72
- 今 开32.19
- 成交量 37.41万股
- 最 低 30.49
- 昨 收 31.67
- 总市值 5.16亿
- 52周最高 43.85
- 市盈率 静 --
- 换手率 2.26%
- 52周最低 6.736
- 委 比 99.75%
- 总股本 1657.04万
- 历史最高 283.00
- 量 比 1.08
- 振 幅 7.04%
- 历史最低 5.231
- 每 手 1
- 风险率 8.89%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Why Agilysys Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket
Agilysys Inc (AGYS) shares rose in pre-market trading after reporting better-than-expected financial results and issuing positive sales guidance. Other notable gainers and losers in pre-market trading include AMST, HAO, MTVA, ONCO, SDA, PIII, VRAX, PURR, BKKT, WOK, BTM, and UBXG.
05-19 16:47
美股大行评级 | 应用材料获17家大行集体上调目标价；Bitdeer 、Forgent 、嘉信理财、Viking等获多家大行上调目标价
今日重点评级关注：Chardan Capital：维持Senti Biosciences"买入"评级，目标价从11美元升至12美元；Ladenburg Thalmann：维持Usio"买入"评级，目标价从5.75美元升至6.25美元
05-18 11:48
HC Wainwright & Co. Maintains Buy on Sutro Biopharma, Raises Price Target to $50
HC Wainwright & Co. analyst Andres Y. Maldonado maintains Sutro Biopharma (NASDAQ:STRO) with a Buy and raises the price target from $28 to $50.
05-15 18:34
Sutro Biopharma Q1 EPS $(2.94) Beats $(3.77) Estimate, Sales $14.523M Beat $8.079M Estimate
Sutro Biopharma (NASDAQ:STRO) reported quarterly losses of $(2.94) per share which beat the analyst consensus estimate of $(3.77) by 22.02 percent. This is a 67.69 percent increase over losses of $(9.10) per share from
05-15 04:45
美股大行评级 | 潜在涨幅128.69%！Immunic获HC Wainwright & Co.升目标价至22美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Immunic"买入"评级，目标价从5美元升至22美元；花旗：维持ServiceNow"买入"评级，目标价从154美元升至158美元
05-01 10:49
Mizuho Initiates Coverage On Sutro Biopharma with Outperform Rating, Announces Price Target of $50
Mizuho analyst Salim Syed initiates coverage on Sutro Biopharma (NASDAQ:STRO) with a Outperform rating and announces Price Target of $50.
04-30 17:38
美股大行评级 | 潜在涨幅15%！15家大行集体上调德州仪器目标价；CSX运输、拉姆研究、金沙集团、马斯可木业、Vertiv Holdings等获多家大行上调目标价
今日重点评级关注：花旗：维持Pegasystems"买入"评级，目标价从70美元升至71美元；巴克莱：维持曼哈顿联合软件"超配"评级，目标价从236美元升至239美元
04-24 12:10
美股大行评级 | 美银证券上调闪迪目标价从900美元升至1080美元；纽约梅隆银行、Onto Innovation、安博、美国合众银行等获多家大行上调目标价
今日重点评级关注：Guggenheim：维持AtaiBeckley Inc."买入"评级，目标价从11美元升至16美元；RBC Capital：维持MeiraGTx Holdings"跑赢大市"评级，目标价从16美元升至24美元
04-20 11:33
Citizens Maintains Market Outperform on Sutro Biopharma, Raises Price Target to $35
Citizens analyst Reni J. Benjamin maintains Sutro Biopharma (NASDAQ:STRO) with a Market Outperform and raises the price target from $23 to $35.
04-17 21:18
